Fisher Funds Management LTD Reduces Position in Humana Inc. $HUM

Fisher Funds Management LTD trimmed its holdings in Humana Inc. (NYSE:HUM) by 6.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 106,667 shares of the insurance provider’s stock after selling 6,800 shares during the period. Fisher Funds Management LTD’s holdings in Humana were worth $18,495,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of HUM. Sound View Wealth Advisors Group LLC lifted its stake in Humana by 3.5% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock valued at $272,000 after acquiring an additional 36 shares during the period. CoreCap Advisors LLC boosted its holdings in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Insigneo Advisory Services LLC grew its stake in shares of Humana by 3.0% in the third quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock worth $386,000 after acquiring an additional 43 shares during the period. Columbus Macro LLC grew its stake in shares of Humana by 5.5% in the fourth quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock worth $210,000 after acquiring an additional 43 shares during the period. Finally, Synovus Financial Corp raised its holdings in shares of Humana by 2.0% during the third quarter. Synovus Financial Corp now owns 2,278 shares of the insurance provider’s stock valued at $593,000 after purchasing an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

NYSE:HUM opened at $360.84 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a 50-day simple moving average of $285.88 and a two-hundred day simple moving average of $241.60. The firm has a market capitalization of $43.32 billion, a PE ratio of 38.59, a P/E/G ratio of 2.05 and a beta of 0.76. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $380.86.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, topping the consensus estimate of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. During the same quarter last year, the company earned $11.58 earnings per share. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. Analysts forecast that Humana Inc. will post 9.04 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s dividend payout ratio is currently 37.86%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of Humana from a “buy” rating to a “buy” rating in a research report on Wednesday, May 20th. Leerink Partners lifted their target price on shares of Humana from $185.00 to $255.00 and gave the stock a “market perform” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. boosted their target price on shares of Humana from $214.00 to $316.00 and gave the company a “neutral” rating in a research note on Monday, June 8th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Humana in a report on Monday, June 1st. Finally, Bank of America raised their price target on Humana from $267.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $291.35.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.